← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV22행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestaleApproved
intralipid (intralipid)
Johnson & Johnson Pharmaceutical R…·Pregnancy Complicated by Low Impla…
54 trials
Overview
Program
intralipid
Overview
Company
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overview
Modality
CGT
Overview
Target
Pregnancy Complicated by Low Implantatio
Overview
Indication
Pregnancy Complicated by Low Implantation
Overview
Phase
APPROVED
Overview
Status
DISCONTINUED
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Established
Overview
Approval status
Approved (flag incomplete)
Technology
Vector
lipid nanoparticles functionalized with randomized poly(ethylene glycol) (rPEG) for mRNA delivery
MoA
Mechanism
targets (TLR9, ALPL, PTGS2) and metabolic pathway
MoA
Biomarker
biomarker
PK/PD
Species
Rat
PK/PD
Animal (cat.)
Rat
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Rat
Toxicology
Animal (cat.)
Rat
Toxicology
Major finding
Evaluation of Intravenous Lipid Emulsion as an Adjunctive Antidote in Experimental Fentanyl Toxicity: Comparison with Naloxone in a Rat Model.. Fentanyl is an extremely potent and highly lipophilic synthetic opioid, whose toxicity is marked by significant respiratory depression and central nervous system impairment. Naloxone is the primary antidote for opioid overdose; however, there is an increas…
Clinical
Safety signal
Evaluation of Intravenous Lipid Emulsion as an Adjunctive Antidote in Experimental Fentanyl Toxicity: Comparison with Naloxone in a Rat Model.. Fentanyl is an extremely potent and highly lipophilic synthetic opioid, whose toxicity is marked by significant respiratory depression and central nervous system impairment. Naloxone is the primary antidote for opioid overdose; however, there is an increas…
Clinical
Program phase
APPROVED